2023年10月24日,复宏汉霖(2696.HK)宣布,基于与宜联生物的合作,公司开发的靶向EGFR的抗体偶联药物(ADC)HLX42的临床前研究数据在2023 ESMO年会上以壁报形式展示。这也是复宏汉霖在ADC治疗领域最新研究成果的首次公开亮相。 尽管多款...
Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above. Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official progr...
[6] Joel Neal et al. CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previousl...
Ascentage Pharma announced that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology Congress. SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ --Ascentage Pharma(6855.HK), ...
All accepted abstracts will be published online in the ESMO Gynae 2023 Abstract Book, a supplement toESMO Open. 注册费: In-person participation includes: Participation in the scientific and educational live sessions with the possibility to interact with the expert panel ...
Abstract # & Link: 289MO Session & Location: ESMO Asia – Gynaecological cancers (ID 28), Hall 401 Date & Time: Friday, December 1, 2023, 11:25 am Singapore time Title: Fruquintinib plus sintilimab in patients with advanced non-small cell lung cancer (“NSCLC”) wit...
Abstract Number: 422P Session: Poster Display Session Leading PI: Jin Li, Shanghai East Hospital, School of Medicine, Tongji University Onsite poster display time: 2024/6/27, 3:35 PM–4:30 PM GMT+2 As of now, no similar dual HER2 blockade therapy for the treatment of HER2-positive gast...
the study results of Phase 2 Clinical Trial in nccRCC was selected as Mini Oral. Andthe study results of HLX07-NPC201 were accepted as a Late-breaking Abstract and were presented by Professor Li Zhang. Moreover, the results of HLX07-CSCC201 were first presented at ESMO Asia 2023, where...
HUTCHMED Limited announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology Congress 2023,
KP, Bruno DS, Kitazono S, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/metastatic NSCLC: initial results from the phase 1b TROPION-Lung04 study. Presented at: 2023 World Conference on Lung Cancer; September 10-12, 2023; Singapore. Abstract OA05.06. ...